PPARγ signalling pathway: molecular mechanisms and therapeutic potential in ligamentum flavum hypertrophy and lumbar spinal stenosis.

backgroundLigamentum flavum hypertrophy (LFH) is a multifactor-mediated degenerative change in the spine. Due to its complex aetiology and pathology, there is no targeted therapy for LFH in the clinic. Therefore, it is urgent to explore its potential mechanism and develop new therapeutic methods, which are conducive to the early recovery of patients. Peroxisome proliferator activated receptor γ (PPARγ), a nuclear receptor regulated by synthetic ligands and endogenous cellular lipids, is involved in a variety of biological processes. Currently, increasing evidence suggests that PPARγ may serve as a new pathway to guide the targeted treatment of LFH. Consequently, therapeutically harnessing the PPARγ signalling pathway to inhibit LFH could become a central focus of current research and clinical translation. MAIN BODY: LFH involves multiple pathological processes, including inflammation, fibrosis, angiogenesis, extracellular matrix (ECM) deposition, apoptosis and proliferation. PPARγ plays a key regulatory role in these biological processes. We further review strategies to modulate or target the PPARγ signalling pathway, highlight the related molecular mechanisms and recent clinical advances, and discuss potential possibilities for clinical translation and future perspectives.

conclusionsAlthough there is no direct evidence to support this, we found through a literature review that PPARγ may be involved in regulating various biological processes involved in the development of LFH. The PPARγ signalling pathway may be a potential therapeutic target for LFH, which provides new insights for future LFH research.